Futura Medical
FUM · AIM · Health Care · mcap £3.3m · 0.2p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 08 Oct 26 | Board change | Board Change and Formal Sale Process Update
Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon® that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces an update |
+0.0% |
| 07 Oct 26 | Results | Positive results from further Eroxon® Intense HUT
Positive results from Additional Eroxon® “Intense” Home User Test |
−2.7% |
| 24 Sep 26 | Result of GM and Total Voting Rights
The following amendment has been made to the 'Result of General Meeting and Total Voting Rights' announcement released on 24/09/26 at 10:36 under RNS No 1721. |
−2.0% | |
| 10 Sep 26 | Board change | Directorate Change
Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Roy |
+0.0% |
| 07 Sep 26 | Fundraise | Oversubscribed Retail Offer
Unless otherwise defined, definitions contained in this announcement have the same meanings as set out in the Company's announcements dated 3 September 2026. |
−24.5% |
| 03 Sep 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
−15.8% | |
| 03 Sep 26 | Fundraise | Retail Offer via the BookBuild Platform
The Company is pleased to announce a retail offer via BookBuild to existing shareholders (the "Retail Offer") of up to 75,000,000 new ordinary shares of 0.2 pence each ("Ordinary Shares") in the capital of the Company (t |
−15.8% |
| 03 Sep 26 | Fundraise | Fundraise and launch of FSP and M&A process
IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF THE FIRM PLACING AND THE CONDITIONAL PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN UK MAR), A |
−15.8% |
| 01 Sep 26 | Results | Unaudited Interim Results 2026
Unaudited interim results for the six months ended 30 June 2026 |
−0.3% |
| 31 Jul 26 | EU Market Launch Clearance
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative, clinically proven sexual health products, is pleased to announce th |
+10.3% | |
| 07 Jul 26 | MED3000 (Eroxon®) European Patent Opposition
Futura Medical announces that the European Patent Office ("EPO") Opposition Division has issued its written decision confirming the revocation of European Patent No. |
−27.8% | |
| 30 Jun 26 | Highly positive data from WSD4000 studies
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to report t |
+4.0% | |
| 29 Jun 26 | New US commercial partner
Agreement with Market Performance Group - a leading omnichannel commerce agency |
−0.4% | |
| 29 Apr 26 | Results | Unaudited Results for the Year Ended 31 Dec 2025
Unaudited Results for the Year Ended 31 December 2025 |
−31.5% |
| 23 Mar 26 | Results | Positive Eroxon® & Eroxon® “Intense” HUT results
Positive results from Eroxon® & new Eroxon® "Intense" Home User Test |
+4.5% |
| 18 Mar 26 | Formal Grant of US Patent
Further to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically pr |
+0.0% | |
| 05 Feb 26 | Patent notice of allowance granted for the US
Patent notice of allowance granted for MED3000 (Eroxon) in the US |
−1.5% | |
| 04 Feb 26 | Trading update | Trading Update
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to provi |
−2.3% |
| 12 Jan 26 | Results | Results of WSD4000 Early Feasibility Study
Highly statistically significant improvement achieved in female sexual function |
+18.8% |
| 10 Dec 25 | Patent notice of allowance granted for China
Patent notice of allowance granted for MED3000 (Eroxon) in China |
−4.4% | |
| 08 Dec 25 | Director dealing | Director/PDMR Shareholding
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that th |
+14.2% |
| 03 Dec 25 | Board change | Directorate Change
Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025. |
−0.9% |
| 14 Nov 25 | PCA Dealing
Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Lom |
−17.7% | |
| 13 Nov 25 | Fundraise | Fundraise of £2.75 million
IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN UK MAR), AS PERMITTED BY UK MAR. |
−28.2% |
Company filings. Not investment advice.